Univariate and multivariate analyses of baseline factors for response, OS, and PFS in 143 patients with newly diagnosed AML treated with ven/aza
| Variable . | CR + CRi . | Univariate . | Multivariate . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate . | Multivariate . | OS . | PFS . | OS . | PFS . | |||||||
| OR (95% CI) . | P . | OR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Sex | 2.11 (1.00-4.45) | .0497 | NR | 0.88 (0.57-1.35) | .5466 | 0.85 (0.56-1.28) | .4401 | NR | NR | |||
| Age ≥65 y | 1.23 (0.50-3.00) | .6509 | NR | 1.54 (0.81-2.90) | .1878 | 1.12 (0.64-1.96) | .6834 | NR | NR | |||
| Baseline bone marrow blast percentage | 1.01 (0.99-1.02) | .4181 | NR | 1.00 (0.99-1.01) | .4963 | 1.00 (0.99-1.01) | .5433 | NR | NR | |||
| FAB M0/M1 | 1.52 (0.73-3.16) | .26611 | NR | 1.14 (0.73-1.77) | .5717 | 0.95 (0.63, 1.45) | .8273 | NR | NR | |||
| FAB M5 | 0.26 (0.08-0.80) | .0187 | 0.18 (0.04-0.76) | 0.0198 | 1.68 (0.87-3.27) | .1249 | 1.51 (0.78-2.92) | .2247 | NR | NR | ||
| ELN risk group: adverse vs intermediate | 0.67 (0.24-1.85) | .4358 | NR | 0.96 (0.56-1.67) | .9688 | 1.01 (0.59-1.73) | .8968 | NR | NR | |||
| KMT2A rearrangement | 0.28 (0.06-1.33) | .1092 | NR | 0.76 (0.24-2.41) | .0049 | 3.32 (1.44-7.66) | Sho | NR | 14.88 (5.13-43.19) | <.0001 | ||
| FLT3 ITD | 0.71 (0.26-1.93) | .5012 | NR | 1.68 (0.96-2.95) | .0686 | 1.48 (0.85-2.59) | .1645 | 2.09 (1.17-3.75) | .0132 | NR | ||
| NPM1 mutation | 3.67 (1.20-11.23) | .0225 | 4.69 (1.30-16.95) | .0185 | 0.68 (0.40-1.16) | .1579 | 0.57 (0.34-0.97) | .0389 | NR | NR | ||
| NPM1 mutation + age ≥65 y | 5.68 (1.27-25.32) | .0228 | * | 0.61 (0.33-1.12) | .1114 | 0.52 (0.28-0.96) | .0367 | * | * | |||
| IDH mutation | 2.79 (1.07-7.29) | .0362 | NR | 0.58 (0.35-0.97) | .0389 | 0.51 (0.31-0.84) | .0084 | NR | NR | |||
| IDH1 mutation | 2.85 (0.61-13.23) | .1816 | † | 0.52 (0.24-1.14) | .1032 | 0.48 (0.22-1.03) | .0606 | † | † | |||
| IDH2 mutation | 2.26 (0.72-7.07) | .1624 | † | 0.73 (0.40-1.35) | .3132 | 0.64 (0.36-1.16) | .1433 | † | † | |||
| RAS pathway mutation | 0.21 (0.09-0.52) | .0007 | 0.29 (0.11-0.77) | .0129 | 2.21 (1.31-3.71) | .0028 | 2.79 (1.69-4.61) | <.0001 | 2.51 (1.47-4.28) | .0007 | 3.01 (1.77-5.13) | <.0001 |
| TP53 mutation | 0.54 (0.22-1.33) | .1801 | NR | 2.46 (1.45-4.16) | .0008 | 2.00 (1.19-3.36) | .0088 | 2.95 (1.69-5.15) | .0001 | 2.46 (1.43-4.25) | .0012 | |
| ASXL1 mutation | 0.54 (0.24-1.20) | .1276 | NR | 1.14 (0.70-1.86) | .5893 | 1.30 (0.82-2.05) | .2637 | NR | NR | |||
| Splice gene mutation | 0.69 (0.32-1.45) | .3215 | NR | 0.94 (0.60-1.48) | .8011 | 0.87 (0.56-1.34) | .5180 | NR | NR | |||
| RUNX1 mutation | 1.56 (0.54-4.53) | .4125 | NR | 0.86 (0.47-1.58) | .6206 | 0.78 (0.44-1.41) | .4151 | NR | NR | |||
| RUNX1 mutation + age ≥65 y | 1.24 (0.42-3.67) | .6959 | * | 0.99 (0.52-1.86) | .9655 | 0.92 (0.50-1.70) | .7988 | * | * | |||
| Secondary AML | 0.65 (0.31-1.35) | .2481 | NR | 1.44 (0.94-2.22) | .0952 | 1.40 (0.92-2.12) | .1129 | NR | NR | |||
| Treatment-related AML | 0.51 (0.21-1.21) | .1275 | NR | 2.13 (1.30, 3.49) | .0026 | 1.86 (1.14-3.01) | .0123 | 1.92 (1.16-3.17) | .0108 | 1.95 (1.18-3.23) | .0093 | |
| Prior therapy for MDS or MPN | 0.23 (0.08-0.65) | .0057 | 0.24 (0.08-0.75) | .0134 | 1.55 (0.82-2.93) | .1821 | 1.78 (0.98-3.22) | .0569 | NR | NR | ||
| Stem cell transplantation | 2.56 (0.90-7.26) | .0766 | NR | 0.20 (0.09-0.44) | <.0001 | 0.28 (0.14-0.54) | .0001 | 0.20 (0.09-0.43) | <.0001 | 0.16 (0.07-0.34) | <.0001 | |
| Variable . | CR + CRi . | Univariate . | Multivariate . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate . | Multivariate . | OS . | PFS . | OS . | PFS . | |||||||
| OR (95% CI) . | P . | OR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Sex | 2.11 (1.00-4.45) | .0497 | NR | 0.88 (0.57-1.35) | .5466 | 0.85 (0.56-1.28) | .4401 | NR | NR | |||
| Age ≥65 y | 1.23 (0.50-3.00) | .6509 | NR | 1.54 (0.81-2.90) | .1878 | 1.12 (0.64-1.96) | .6834 | NR | NR | |||
| Baseline bone marrow blast percentage | 1.01 (0.99-1.02) | .4181 | NR | 1.00 (0.99-1.01) | .4963 | 1.00 (0.99-1.01) | .5433 | NR | NR | |||
| FAB M0/M1 | 1.52 (0.73-3.16) | .26611 | NR | 1.14 (0.73-1.77) | .5717 | 0.95 (0.63, 1.45) | .8273 | NR | NR | |||
| FAB M5 | 0.26 (0.08-0.80) | .0187 | 0.18 (0.04-0.76) | 0.0198 | 1.68 (0.87-3.27) | .1249 | 1.51 (0.78-2.92) | .2247 | NR | NR | ||
| ELN risk group: adverse vs intermediate | 0.67 (0.24-1.85) | .4358 | NR | 0.96 (0.56-1.67) | .9688 | 1.01 (0.59-1.73) | .8968 | NR | NR | |||
| KMT2A rearrangement | 0.28 (0.06-1.33) | .1092 | NR | 0.76 (0.24-2.41) | .0049 | 3.32 (1.44-7.66) | Sho | NR | 14.88 (5.13-43.19) | <.0001 | ||
| FLT3 ITD | 0.71 (0.26-1.93) | .5012 | NR | 1.68 (0.96-2.95) | .0686 | 1.48 (0.85-2.59) | .1645 | 2.09 (1.17-3.75) | .0132 | NR | ||
| NPM1 mutation | 3.67 (1.20-11.23) | .0225 | 4.69 (1.30-16.95) | .0185 | 0.68 (0.40-1.16) | .1579 | 0.57 (0.34-0.97) | .0389 | NR | NR | ||
| NPM1 mutation + age ≥65 y | 5.68 (1.27-25.32) | .0228 | * | 0.61 (0.33-1.12) | .1114 | 0.52 (0.28-0.96) | .0367 | * | * | |||
| IDH mutation | 2.79 (1.07-7.29) | .0362 | NR | 0.58 (0.35-0.97) | .0389 | 0.51 (0.31-0.84) | .0084 | NR | NR | |||
| IDH1 mutation | 2.85 (0.61-13.23) | .1816 | † | 0.52 (0.24-1.14) | .1032 | 0.48 (0.22-1.03) | .0606 | † | † | |||
| IDH2 mutation | 2.26 (0.72-7.07) | .1624 | † | 0.73 (0.40-1.35) | .3132 | 0.64 (0.36-1.16) | .1433 | † | † | |||
| RAS pathway mutation | 0.21 (0.09-0.52) | .0007 | 0.29 (0.11-0.77) | .0129 | 2.21 (1.31-3.71) | .0028 | 2.79 (1.69-4.61) | <.0001 | 2.51 (1.47-4.28) | .0007 | 3.01 (1.77-5.13) | <.0001 |
| TP53 mutation | 0.54 (0.22-1.33) | .1801 | NR | 2.46 (1.45-4.16) | .0008 | 2.00 (1.19-3.36) | .0088 | 2.95 (1.69-5.15) | .0001 | 2.46 (1.43-4.25) | .0012 | |
| ASXL1 mutation | 0.54 (0.24-1.20) | .1276 | NR | 1.14 (0.70-1.86) | .5893 | 1.30 (0.82-2.05) | .2637 | NR | NR | |||
| Splice gene mutation | 0.69 (0.32-1.45) | .3215 | NR | 0.94 (0.60-1.48) | .8011 | 0.87 (0.56-1.34) | .5180 | NR | NR | |||
| RUNX1 mutation | 1.56 (0.54-4.53) | .4125 | NR | 0.86 (0.47-1.58) | .6206 | 0.78 (0.44-1.41) | .4151 | NR | NR | |||
| RUNX1 mutation + age ≥65 y | 1.24 (0.42-3.67) | .6959 | * | 0.99 (0.52-1.86) | .9655 | 0.92 (0.50-1.70) | .7988 | * | * | |||
| Secondary AML | 0.65 (0.31-1.35) | .2481 | NR | 1.44 (0.94-2.22) | .0952 | 1.40 (0.92-2.12) | .1129 | NR | NR | |||
| Treatment-related AML | 0.51 (0.21-1.21) | .1275 | NR | 2.13 (1.30, 3.49) | .0026 | 1.86 (1.14-3.01) | .0123 | 1.92 (1.16-3.17) | .0108 | 1.95 (1.18-3.23) | .0093 | |
| Prior therapy for MDS or MPN | 0.23 (0.08-0.65) | .0057 | 0.24 (0.08-0.75) | .0134 | 1.55 (0.82-2.93) | .1821 | 1.78 (0.98-3.22) | .0569 | NR | NR | ||
| Stem cell transplantation | 2.56 (0.90-7.26) | .0766 | NR | 0.20 (0.09-0.44) | <.0001 | 0.28 (0.14-0.54) | .0001 | 0.20 (0.09-0.43) | <.0001 | 0.16 (0.07-0.34) | <.0001 | |
CI, confidence interval; HR, hazard ratio; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NR, not relevant as multivariate predictor; OR, odds ratio.
Compound variables were not included for analysis in multivariate modeling.
For correlated variables (IDH and IDH1/2), only 1 variable (IDH) was included.